Holen Sie sich die Stockscreener-App
2.16
0.46%
-0.010
Schlusskurs vom Vortag:
$2.17
Offen:
$2.17
24-Stunden-Volumen:
78,178
Relative Volume:
0.64
Marktkapitalisierung:
$8.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.24M
KGV:
-0.3867
EPS:
-5.5853
Netto-Cashflow:
$-8.09M
1W Leistung:
+4.85%
1M Leistung:
-8.47%
6M Leistung:
-34.94%
1J Leistung:
-80.49%
1-Tages-Spanne:
$2.0899
$2.24
1-Wochen-Bereich:
$2.04
$2.31
52-Wochen-Spanne:
$1.88
$12.06
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
3500 LENOX RD. NE, ATLANTA
Vergleichen Sie ALZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.16 | 8.25M | 0 | -6.24M | -8.09M | -5.5853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Alzamend Neuro, Inc. SEC 10-Q Report - TradingView
Is Alzamend Neuro Inc stock attractive for passive investorsWeekly Investment Summary & Weekly Top Gainers Alerts - BỘ NỘI VỤ
Why Alzamend Neuro Inc. stock remains undervaluedJuly 2025 Analyst Calls & High Accuracy Trade Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
Alzamend Neuro Mourns Loss of Director Andrew Woo - MSN
Is Alzamend Neuro Inc. stock attractive for passive investors2025 Earnings Impact & Daily Profit Focused Stock Screening - BỘ NỘI VỤ
Alzamend Neuro: Will Topline Data Spark Investor Interest? - RTTNews
Alzamend Neuro's AL001 formulation highlights its potential to treat disorders such a Alzheimer's - SelectScience
What margin trends mean for Alzamend Neuro Inc. stockWeekly Market Outlook & Verified Swing Trading Watchlists - newser.com
Why Alzamend Neuro Inc. stock could see breakout soonProduct Launch & High Return Trade Opportunity Guides - newser.com
Why Alzamend Neuro Inc. stock could benefit from AI revolutionTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Can Alzamend Neuro Inc. stock sustain revenue growthMarket Risk Analysis & Pattern Based Trade Signal System - newser.com
Will Alzamend Neuro Inc. stock rally after Fed decisionsJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - newser.com
Will Alzamend Neuro Inc. stock reach all time highs in 2025Exit Point & Daily Technical Forecast Reports - newser.com
Alzamend completes clinical portion of phase II trial for lithium therapy - Investing.com Nigeria
Published on: 2025-11-19 13:20:00 - newser.com
Alzamend Neuro announces passing of board member Andrew H. Woo By Investing.com - Investing.com Australia
Comparing Alzamend Neuro Inc. in custom built stock radarsWeekly Risk Summary & Weekly Momentum Picks - newser.com
Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital - MarketScreener
Alzamend rises after completing mid-stage brain lithium study - TradingView
Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - Benzinga
Multi asset correlation models including Alzamend Neuro Inc.Oil Prices & Fast Exit/Entry Strategy Plans - newser.com
Is Alzamend Neuro Inc. stock cheap compared to fundamentalsWeekly Trend Summary & Safe Capital Growth Plans - newser.com
Alzamend Neuro announces passing of board member Andrew H. Woo - Investing.com
Alzamend Neuro Announces Passing of Board Member Andrew H. Woo - TradingView
[8-K] Alzamend Neuro, Inc. Reports Material Event | ALZN SEC FilingForm 8-K - Stock Titan
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):